Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...

M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...

Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business ...

Adjusted free cash flow significantly declined to $92 million from $459 million in Q4 2023. Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments ...